John C. Bell

John C Bell, PhD, is an internationally recognized expert in the use of oncolytic viruses for the treatment of cancer. He formed and directs the Canadian Consortium on Oncolytic Viruses, a cross-Canada multidisciplinary group developing virus-based cancer therapies. He is the Scientific Director of BioCanRx, a network of centers of excellence that develops and clinically tests new immunotherapies for the treatment of cancer. He co-founded biotechnology companies developing oncolytic viruses (Jennerex and Turnstone Biologics). John is a Senior Scientist at the Ottawa Hospital Research Institute (OHRI), a research institution affiliated with the University of Ottawa. John began his career as an independent researcher in the Department of Biochemistry at McGill University.

For 30 years, its research programs have been funded by peer-reviewed grants. He is the author of more than 400 publications.

He did his postdoctoral studies at the Medical Research Council in London, England, and obtained his PhD in Virology and Immunology from McMaster University in Ontario, Canada.